NasdaqGM:WVEPharmaceuticals
How Mixed Q4 Results, Obesity Data and Cash Runway News At Wave Life Sciences (WVE) Has Changed Its Investment Story
Wave Life Sciences has reported its fourth-quarter and full-year 2025 results, with quarterly revenue falling to US$17.24 million from US$83.75 million and the company moving from a net income of US$29.25 million to a net loss of US$53.18 million, while also outlining progress across its RNA-based obesity and alpha-1 antitrypsin deficiency programs.
Despite wider losses, Wave highlighted interim obesity and alpha-1 antitrypsin deficiency data, a cash position of US$602.10 million funding...